PATENT CLAIM ANALYSIS

Application Number: 16195361
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["514", "236500"]

Abstract:
The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed.

Claim (Index 12):
The method of  claim 1 , wherein the administering causes a reduction in apoptosis of muscle cells in the subject.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 98.0
- Lexical Diversity: 1.40678
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16166031', '14491599', '15780509', '14234413', '15549072']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7884439805218171
- 35 USC 102 Novelty (BERT): 0.757865984521422
- Combined Prediction Score: 0.7853861809217776
- Mean Citation Score: 423.825876
- Max Citation Score: 891.4147
- Similarity Product: 856.6808442450642

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test